Related Experiment Video
Updated: Jun 11, 2026
06:48
Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium
Published on: August 7, 2015
Two-Port Vitrectomy-free Subretinal Gene Therapy for Bietti Crystalline Dystrophy
Xiuju Chen1, Xiangdong Luo, Xiaoxin Li
1Retina Department, Xiamen University Xiamen Eye Center, Xiamen, China.
Retina (Philadelphia, Pa.)
|June 10, 2026
Summary
This study shows a modified, vitrectomy-free subretinal injection is safe and feasible for Bietti crystalline dystrophy gene therapy. The technique improved vision in most patients with a low risk of early cataract formation.
Area of Science:
- Ophthalmology
- Gene Therapy
- Retinal Diseases
Background:
- Bietti crystalline dystrophy is a rare inherited retinal disease.
- Current gene therapy delivery methods can be complex and carry risks.
Purpose of the Study:
- To assess the safety and feasibility of a simplified, two-port, vitrectomy-free subretinal injection for gene therapy in Bietti crystalline dystrophy patients.
Main Methods:
- Nineteen patients with Bietti crystalline dystrophy received subretinal gene delivery via a two-port, vitrectomy-free approach.
- Anterior chamber paracentesis managed intraocular pressure.
- Patients were monitored for up to 2 years for immune response, retinal integrity, cataracts, and visual changes.
Main Results:
- All procedures were completed without complications; surgery averaged 9-14 minutes.
- Subretinal bleb resolution was rapid in most cases.
- Visual acuity improved in 79% at 6 months, 61% at 1 year, and 50% at 2 years; no cataracts formed.
Conclusions:
- The simplified, vitrectomy-free subretinal delivery technique is feasible and safe for Bietti crystalline dystrophy.
- This method may lower the risk of early cataract development.
- Further comparative studies with longer follow-up are needed to confirm these preliminary findings.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...